References
- Adhim Z, Otsuki N, Kitamoto J, et al (2013). Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines. Acta Oto-Laryngologica, 133, 761-71. https://doi.org/10.3109/00016489.2013.773405
- Allgood VE, Cidlowski JA (1992). Vitamine B6 modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. J Biol Chem, 267, 3819-24.
- Andersson S, Rylander E, Strand A, et al (2001). The significance of p53codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer, 85, 1153-6. https://doi.org/10.1054/bjoc.2001.2085
- Bergamaschi D, Samuels Y, Sullivan A, et al (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet, 38, 1133-41. https://doi.org/10.1038/ng1879
- Blagosklonny MV (1997). Loss of function and p53 protein stabilization. Oncogene, 15, 1889-93. https://doi.org/10.1038/sj.onc.1201374
- Chen G, Zhang S, He X, et al (2014). Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets Therapy, 7, 1901-9.
- Drewinko B, Yang LY, Leibovitz A, et al (1984). Cellular discriminants for a biological classification of human colon carcinoma. Cancer Res, 44, 4241-53.
- Feng Z, Zhang C, Kang H-J, et al (2011). Regulation of female reproduction by p53 and its family members. FASEB J, 25, 2245-55. https://doi.org/10.1096/fj.10-180166
- Habbous S, Pang V, Eng L, et al (2012). p53Arg72Pro polymorphism, HPV status and initiation progression and development of cervical cancer: A systematic review and meta-analysis. Clin Cancer Res, 18, 6407-15. https://doi.org/10.1158/1078-0432.CCR-12-1983
- Hougardy BMT, Maduro JH, van der Zee ADJ, et al (2006). Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer, 118, 1892-900. https://doi.org/10.1002/ijc.21580
- Ishiwata I, Ishiwata C, Soma M, et al (1984). Establish01ment of human endometrial adenocarcinoma cell line containing estradiol-17beta and progesterone receptors. Gynecol Oncol, 17, 281-90. https://doi.org/10.1016/0090-8258(84)90212-9
- Jeong BS, Hu W, Belyi V, et al (2010). Differential levels of transcription of p53-regulated genes by the arginine/ proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J, 24, 1347-53. https://doi.org/10.1096/fj.09-146001
- Kajitani K, Honda K, Terada H, et al (2012). Estrogen response element enhances adenovirus-mediated transfer of the p53 gene according to codon 72 polymorphisms and cellular estrogen receptor expression. J Cancer Ther Res, 31, 1-8.
- Klinge CM (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res, 29, 2905-19. https://doi.org/10.1093/nar/29.14.2905
- Klug SJ, Ressing M, Koenig J, et al (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol, 10, 772-84. https://doi.org/10.1016/S1470-2045(09)70187-1
- Kumar NS, Richer J, Owen G, et al (1998). Selective downregulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. Cancer Res, 58, 1860-5.
- Kuner R, Vogt M, Sultmann H, et al (2007). Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med, 85, 1253-62. https://doi.org/10.1007/s00109-007-0230-1
- Kruse JP, Gu W (2009). Modes of p53 regulation. Cell, 137, 609-22. https://doi.org/10.1016/j.cell.2009.04.050
- Li X, Li Y, Hu Z, et al (2013). Plasmid-based E6-specific siRNA and co-expressioin of wild type p53 suppresses the growth of cervical cancer in vitro and in vivo. Cancer Lett, 335, 242-50. https://doi.org/10.1016/j.canlet.2013.02.034
- Liu G, Xia T, Chen X (2003). The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem, 278, 17557-65. https://doi.org/10.1074/jbc.M210696200
- Menendez D, Inga A, Resnick MA (2010). Potentiating the p53 network. Discov Med, 10, 94-100.
- Nunobiki O, Ueda M, Toji E, et al (2011). Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. SAGE-Hindawi Access Res Pathol Res Int.
- Scheffner M, Werness BA, Huibregtse JM, et al (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-36. https://doi.org/10.1016/0092-8674(90)90409-8
- Storey A, Thomas M, Kalita A, et al (1998). Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature, 393, 229-34 https://doi.org/10.1038/30400
- Tan S, Hougardy BMT, Meersma GJ, et al (2012). Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells. Mol Parmacol, 81, 701-9.
- Trigiante G, Lu X(2006). ASPPs and cancer. Nat Rev, 6, 217-26. https://doi.org/10.1038/nrc1818
- Zhi X, Honda K, Sumi T, et al (2007). Esyradiol-17beta regulates vascular endothelial growth factor and Bcl-2 expression in HHUA cells. Int J Oncol, 31, 1333-8
Cited by
- Clinical Significance of Low 2-Methoxyestradiol Levels in Serum and Tissue of Recurrent Juvenile-Onset Laryngeal Papillomatosis vol.158, pp.3, 2018, https://doi.org/10.1177/0194599817740578